GERD and acid reflux cases are rising fast across India, and doctors are shifting prescriptions from traditional PPIs to Vonoprazan, a faster-acting Potassium-Competitive Acid Blocker. Janus Biotech's latest blog explores why demand for Vonoprazan PCD pharma franchise is climbing, the market trends backing this opportunity, and how a Vonoprazan PCD franchise with monopoly rights, low investment & WHO-GMP certified manufacturing can help you tap into the growing gastro segment. Read the full article & contact us: https://janus.co.in/future-of-vonoprazan-pcd-pharma-business-in-india/